MedPath

Echo-Guided Tricuspid Valve Surgery Vs. Conservative Approach

Not Applicable
Conditions
Tricuspid Valve Insufficiency
Interventions
Procedure: Tricuspid Valve Repair
Procedure: Left-sided valve surgery
Registration Number
NCT03278418
Lead Sponsor
Ettore Sansavini Health Science Foundation
Brief Summary

Patients elected to undergo any type of left-sided valve surgery (either repair or replacement) with non severe tricuspid regurgitation and tricuspid annular dilation will be screened. Consenting patients fulfilling all inclusion and exclusion criteria will be included in the study and assigned to elective left-sided valve replacement or repair with or without concomitant tricuspid valve repair in a 1:1 fashion, using a blocked randomization scheme balanced within center.

Detailed Description

The present study is designed as a prospective, multicentre, multinational, randomized, 2-arm parallel group trial. Participating centres are selected based on previous experience with the surgical technique and standardised echo imaging. Each center is expected to contribute 70 patients over a 12 months enrolment period.

Patients elected to undergo any type of left-sided valve surgery (either repair or replacement) with non severe tricuspid regurgitation and tricuspid annular dilation will be screened. Consenting patients fulfilling all inclusion and exclusion criteria will be included in the study and assigned to elective left-sided valve replacement or repair with or without concomitant tricuspid valve repair in a 1:1 fashion, using a blocked randomization scheme balanced within center.

After discharge patients will be assessed at 1, 12, 24 and 36 months after surgery.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
280
Inclusion Criteria
  • Patients undergoing left-sided valve surgery for left-sided valve disease
  • Presence of non-severe TR and tricuspid annular dilation (>40 mm or > 21 mm/m2 BSA) determined by echocardiography
  • Age ≥ 18 years
  • Capability to sign Informed Consent and Release of Medical Information forms
Exclusion Criteria
  • Preoperative severe TR
  • Structural / organic tricuspid valve disease
  • Tricuspid annulus ≤40 mm (or ≤ 21 mm/m2 BSA) on preoperative TTE
  • Implanted pacemaker or defibrillator, where the leads cross the tricuspid valve from the right atrium into the RV
  • Any type of reoperative surgery
  • Concomitant cardiac surgery other than atrial fibrillation correction surgery (pulmonary vein isolation, Maze procedure, left atrial appendage closure) or closure of patent foramen ovale or atrial septal defect (for example, concomitant coronary artery bypass graft or aortic surgery)
  • Cardiogenic shock at the time of randomization
  • ST-elevated myocardial infarction requiring intervention within 7 days prior to randomization
  • Evidence of cirrhosis or hepatic synthetic failure
  • Severe, irreversible pulmonary hypertension in the judgment of the investigator
  • Pregnancy at the time of randomization
  • Any concurrent disease with life expectancy < 1 year
  • Patient unable or unwilling to provide informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Tricuspid Valve RepairLeft-sided valve surgeryConcomitant tricuspid valve repair in patients undergoing left-sided valve surgery
left-sided valve surgeryLeft-sided valve surgeryNo concomitant tricuspid valve repair in patients in pts undergoing left-sided valve surgery
Tricuspid Valve RepairTricuspid Valve RepairConcomitant tricuspid valve repair in patients undergoing left-sided valve surgery
Primary Outcome Measures
NameTimeMethod
Significant TR (moderate or severe)3 years

To compare in a prospective and randomized way the effect of two different strategies on significant TR (moderate or severe) in patients undergoing surgery for left heart valve disease of any type as assessed by the Core lab evaluation of the echocardiogram. In the echocardiogram images TR by jet area will be grouped as moderate (5-10 cm2) or severe (\>10 cm2).

Secondary Outcome Measures
NameTimeMethod
Significant TR (moderate or severe)1 and 2 years

To compare in a prospective and randomized way the effect of two different strategies on significant TR (moderate or severe) in patients undergoing surgery for left heart valve disease of any type as assessed by the Core lab evaluation of the echocardiogram. In the echocardiogram images TR by jet area will be grouped as moderate (5-10 cm2) or severe (\>10 cm2).

Overall TR (mild, moderate, severe)1, 2 and 3 years

To compare in a prospective and randomized way the effect of two different strategies on significant TR (moderate or severe) in patients undergoing surgery for left heart valve disease of any type as assessed by the Core lab evaluation of the echocardiogram. In the echocardiogram images TR by jet area will be grouped as non severe (≤10 cm2; mild \<5 cm2, moderate = 5-10 cm2), or severe (\>10 cm2).

Event free survival3 years

Safety evaluation will rely on all AE/SAEs subsequent to spontaneous reporting, or to detection of clinically relevant abnormalities on physical examinations, vital signs, ECG, and laboratory tests

Mild TR1,2 and 3 years

To compare in a prospective and randomized way the effect of two different strategies on significant TR (moderate or severe) in patients undergoing surgery for left heart valve disease of any type as assessed by the Core lab evaluation of the echocardiogram. In the echocardiogram images TR by jet area will be grouped as non severe (≤10 cm2) or mild (\<5 cm2).

RV function1, 2 and 3 years

To compare the effect of the 2 strategies for non-severe TR described above on the evaluation of reverse right ventricle (RV) remodelling, assessed as reduction/modification of the end diastolic and end systolic RV diameters.

Pulmonary Artery Pressure (PAP)1, 2 and 3 years

To compare the effect of the 2 strategies for non-severe TR on pulmonary artery pressure (PAP)

Trial Locations

Locations (4)

IRCCS Policlinico San Donato

🇮🇹

Milano, Italy

IRCCS Opsedale San Raffaele

🇮🇹

Milano, Italy

Maria Eleonora Hospital

🇮🇹

Palermo, Italy

Maria Cecilia Hospital

🇮🇹

Cotignola, Ravenna, Italy

© Copyright 2025. All Rights Reserved by MedPath